Food and Drug Administration Center for Drug Evaluation and Research

Process Analytical Technologies Subcommittee of the Advisory Committee for Pharmaceutical Science

Gaithersburg Hilton, 620 Perry Parkway, Gaithersburg, MD

June 12, 2002 AGENDA

| | - |
|--------------|---|
| 8:30 8:40 | Call to Order: Thomas Layloff, Ph.D., Acting Chair Meeting Statement: Kathleen Reedy, RDH, MS, Executive Secretary (acting) |
| 8:50 | Introduction, Overview, Training and Objectives of Subcommittee Ajaz Hussain, Ph.D., Deputy Director, Office of Pharmaceutical Science |
| 9:35 | Subcommittee Discussion on Training |
| 10:20 | Break |
| 10:35 | Regulatory Challenges: PAT Applications in NDAs: Jeffrey Blumenstein, Ph.D., Pfizer Inc. PAT Application in ANDAs: Steven Bende PAT Application Post-Approval: Dhiren N. Shah, Ph.D., Aventis Pharmaceuticals PAT Validation/GMP issues: Henry Avallone, B.Sc., Johnson & Johnson |
| 11:30 | Subcommittee Discussion on Regulatory Risk |
| 12:00 | Lunch |
| 1:00 | Open Public Hearing: Justin O. Neway, Ph.D: Aegis Analytical Corporation Li Peckan, Allan Wilson: The 2080 Group Dan Klevisha, Tom Tague, Ph.D., Jon Goode, Ph.D: Bruker Optics |
| 2:00 | Subcommittee Discussion on Regulatory Risks and Training |
| 3:00 | Break |
| 3:15 | Subcommittee Discussion |
| 4:30 | Working Group Sessions and Strategy |
| | |

5:00 Adjourn

Food and Drug Administration Center for Drug Evaluation and Research

Process Analytical Technologies Subcommittee of the Advisory Committee for Pharmaceutical Science

Gaithersburg Hilton, 620 Perry Parkway, Gaithersburg, MD

June 13, 2002 AGENDA

| 8:00 8:10 | Call to Order: Thomas Layloff, Ph.D., Acting Chair Meeting Statement: Kathleen Reedy, RDH, MS, Executive Secretary (acting) |
|--------------|---|
| 8:15 | Charge to Working Groups: Thomas Layloff, Ph.D., Acting Chair |
| 8:30 | Working Group Discussions |
| 10:00 | Break |
| 10:15 | Working Group Discussions |
| 11:15 | Consensus and Summary Preparation |
| 12:00 | Lunch |
| 1:00 | Open Public Hearing |
| | Working Group Summaries: |
| 1:30 | Product and Process Development: Judy P. Boehlert, Ph.D., Chair |
| 1:45 | Subcommittee Question and Answers |
| 2:15 | Process and Analytical Validation: Arthur H. Kibbe, Ph.D., Chair |
| 2:30 | Subcommittee Question and Answers |
| 3:00 | Break |
| 3:15 | Subcommittee Discussion |
| 4:15 | Summary: Ajaz Hussain, Ph.D., Deputy Director, Office of Pharmaceutical Science |
| 4:25 | Closing Remarks: Thomas Layloff, Ph.D., Acting Chair |

4:30 Adjourn